Myriad Genetics, Inc. (MYGN)
| Market Cap | 2.69B |
| Revenue (ttm) | 662.30M |
| Net Income (ttm) | -97.30M |
| Shares Out | 77.20M |
| EPS (ttm) | 0.26 |
| PE Ratio | 132.67 |
| Forward PE | 120.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 277,549 |
| Open | 34.76 |
| Previous Close | 34.47 |
| Day's Range | 33.85 - 35.31 |
| 52-Week Range | 11.76 - 36.95 |
| Beta | 1.58 |
| Analysts | Hold |
| Price Target | 30.25 (-13.0%) |
| Est. Earnings Date | Nov 9, 2021 |
About MYGN
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with...
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for MYGN stock is "Hold." The 12-month stock price forecast is 30.25, which is a decrease of -12.97% from the latest price.
News
Myriad Genetics Completes Sale of Myriad Autoimmune's Vectra Testing Business to LabCorp
SALT LAKE CITY, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has completed the sale of select oper...
Only 8% of people remain hopeful after depression medication fails them, according to GeneSight® Mental Health Monito...
SALT LAKE CITY, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Depression medication trial and error is far too common – and may result in additional mental health challenges.
4 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Myriad Genetics (MYGN) Q2 Earnings Beat, Gross Margin Rises
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q2 sales despite a challenging business environment.
What's Up With Myriad Genetics Shares Trading Higher Tuesday?
Myriad Genetics, Inc. (NASDAQ:MYGN) shares are trading higher by 12.4% at $34.68 Tuesday afternoon after the company reported better-than-expected fourth-quarter EPS and sales results. Myriad Genetics r...
Myriad Genetics (MYGN) Beats Q2 Earnings and Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of 271.43% and 13.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics Delivers Strong Revenue and Earnings Growth in June 2021 Quarter, Continues to Execute on Strategic G...
SALT LAKE CITY, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its second quarter ended...
Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score ...
SALT LAKE CITY, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Advancing its mission to expand access to genetic testing, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, tod...
Myriad Genetics to Release Second Quarter Financial Results on August 3, 2021
SALT LAKE CITY, July 28, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it will hold its quarterly earnings confe...
New research reveals most Americans can't identify the symptoms of depression
GeneSight® Mental Health Monitor finds large gap between what Americans think and what they actually know about recognizing depression GeneSight® Mental Health Monitor finds large gap between what Ameri...
Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities
SALT LAKE CITY, July 21, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for a new recommendation statement...
Myriad Genetics (MYGN) Divests Myriad RBM to Focus on Core Units
Myriad Genetics' (MYGN) new divesture will enable company to accelerate the execution of transformation plan and drive growth.
Myriad Genetics Completes Sale of Myriad RBM to IQVIA's Q2 Solutions
SALT LAKE CITY, July 01, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has completed the sale of its wholly-o...
Thomas P. Slavin, M.D., Named Chief Medical Officer for Myriad Genetics
Dr. Slavin Brings Deep Clinical, Academic and Industry Experience to New Role Dr. Slavin Brings Deep Clinical, Academic and Industry Experience to New Role
Alliance Data, Cimarex Energy, Myriad Genetics, Nestle and More Tuesday Afternoon Analyst Research Calls
The markets were lower across the board on Tuesday afternoon. All eyes on Wall Street are focused on the two-day Federal Reserve meeting, which began Tuesday, as many are waiting to hear how the narrati...
Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference
SALT LAKE CITY, June 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company's transf...
Why Is Myriad (MYGN) Down 11.5% Since Last Earnings Report?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
Myriad Genetics (MYGN) Sells myPath to Focus on Core Units
Myriad Genetics' (MYGN) new divesture will provide the company with growth capital for future investments.
Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences
SALT LAKE CITY, June 01, 2021 (GLOBE NEWSWIRE) -- On May 28, 2021, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsid...
Myriad Genetics' (MYGN) GeneSight Test Rollout Initiated by IPM
Myriad Genetics' (MYGN) GeneSight testing distribution initiated through IPM will help clinicians and patients assess individual's response to certain medications.
IPM Launches GeneSight® Pharmacogenomics Program for Depression and Anxiety
FRESNO, Calif., May 27, 2021 /PRNewswire/ -- Integrated Prescription Management (IPM), a leading pharmacy benefits management (PBM) company, now offers pharmacogenomics testing for patients suffering fr...
Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions
SALT LAKE CITY, May 24, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has signed a definitive agreement to sell My...
Myriad Genetics Appoints Melissa Gonzales to Lead Women's Health Business
New President Brings Proven Track Record in Women's Health; Direct to Physician and Direct to Patient Commercial Expertise New President Brings Proven Track Record in Women's Health; Direct to Physician...
Myriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of Al...
Study Is First to Validate New Polygenic Risk Assessment for All; Company Aims to Improve Access and Reduce Disparities in Genetic Testing Study Is First to Validate New Polygenic Risk Assessment for Al...
Myriad Genetics (MYGN) Beats on Q1 Earnings and Revenues
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q1 sales despite pandemic-led business challenges.